18
Jan
On January 13, 2017, the U.S. Food and Drug Administration (FDA) issued a discussion paper1 in which the FDA announced that it would delay issuing final guidance on laboratory developed tests (LDTs).2 The FDA cited two reasons for the delay: i) to allow further public discussion on an appropriate oversight approach; and ii) to give Congress, via its oversight committees, the opportunity to develop a legislative solution to LDT oversight.
In lieu of issuing final guidance, the FDA synthesized a...